Skip to content

Author

Elsa Ferris

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Clinical, cytogenetic, and germline genetic determinants of arterial thromboembolism in IMiD-treated multiple myeloma

Immunomodulatory drugs (IMiDs) are associated with an increased risk of arterial thromboembolism (ATE) in multiple myeloma (MM), but determinants and mechanisms remain poorly defined. We evaluated incidence, timing, and clinical risk factors in 4287 patients with newly diagnosed MM from the Myeloma-XI-trial; all re...

S. Beer, D. Cairns, M. Went et al. · 0 citations
Open access Sep 2026

Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial.

BACKGROUND High-risk multiple myeloma, defined by two or more high-risk cytogenetic abnormalities (HRCAs), high-risk gene expression profiling (GEP), or plasma cell leukaemia, remains associated with poor long-term outcomes despite quadruplet induction therapy. OPTIMUM showed that intensified induction, extended consol...

Martin F. Kaiser, R. Phillip, Sarah R. Brown et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.